Larry Wood, President and CEO, stated total revenue for the third quarter of 2025 was $83.3 million, highlighting strong execution, primarily driven by U.S. capital systems shipped, totaling 58 in the ...

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM ® and HYDROS ® Robotic ...

In early October 2026, PROCEPT BioRobotics added veteran cardiac surgeon Dr. Michael Mack to its board as an independent Class II director, while also facing a newly filed securities lawsuit alleging ...

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

META: $214.48 million (5.3% of AUM) GOOGL: $171.23 million (4.2% of AUM) AMZN: $161.25 million (4.0% of AUM) NVDA: $149.51 million (3.7% of AUM) V: $137.50 million (3.4% of AUM) As of October 21, 2025 ...

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...

Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...

View PROCEPT BioRobotics Corp. PRCT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Why this governance shift at PROCEPT BioRobotics matters for investors A fresh investor lawsuit and the appointment of ...

Develops, manufactures, and sells the AquaBeam Robotic System and Aquablation therapy for minimally invasive urologic surgery, primarily targeting benign prostatic hyperplasia (BPH). Generates revenue ...

PROCEPT BioRobotics stock (ISIN US74276L1052) closed at USD 17.16 on Nasdaq on October 2, 2026, gaining 0.82 percent from the prior close. The same-day filing expanded the board from nine to ten ...